BAMF
AXSM icon

BI Asset Management Fondsmaeglerselskab’s Axsome Therapeutics AXSM Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-404
Closed -$47K – 760
2025
Q1 		$47K Buy
+404
New +$46K ﹤0.01% 805
2020
Q2 		– Sell
-15,891
Closed -$935K – 421
2020
Q1 		$935K Buy
+15,891
New +$1.29M 0.06% 254

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's AXSM Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 404 shares — an estimated $47K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in AXSM in Q1 2020 and held it in 2 quarters. The position peaked at $935K in Q1 2020. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 404 Axsome Therapeutics shares in Q2 2025, an estimated $47K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Axsome Therapeutics in Q1 2020 and held it in 2 quarters.
  • BI Asset Management Fondsmaeglerselskab's Axsome Therapeutics position peaked at $935K in Q1 2020.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.